Eli Lilly (LLY) is scheduled to release its Q1 earnings on May 1, and analysts continue to stay positive, holding onto Buy ...

Eli Lilly shares were up by 0.22% to $746.04 on Wednesday at 1:13 pm. On Tuesday, the stock fell by 8% after the company forecast fourth-quarter sales of weight-loss drug Zepbound below Wall ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...

Eli Lilly and Co. (LLY) emerged as a beacon of optimism last week in a market filled with uncertainty and volatility. Shares ...

The trial met its primary objectives, showing the pill’s effectiveness in helping patients with Type 2 diabetes achieve ...

Eli Lilly reports positive late-stage data for its weight-loss pill. BMO analyst says Lilly's update will weigh on shares of ...

Shares in pharmaceuticals firm Eli Lilly (LLY) rose today after it said it was suing companies ripping off its weight-loss ...

With Q4 behind us, let’s have a look at Eli Lilly (NYSE:LLY ... not the investors who make buy and sell decisions). The stock is down 11.8% since reporting and currently trades at $743.98.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.